Quest Diagnostics ( (DGX) ) has released its Q1 earnings. Here is a breakdown of the information Quest Diagnostics presented to its investors.
Quest Diagnostics Incorporated, a prominent provider of diagnostic information services, plays a crucial role in the healthcare sector by offering laboratory testing and diagnostic insights to improve health outcomes. The company serves a significant portion of the U.S. population, including one in three adult Americans and half of the physicians and hospitals.
In the first quarter of 2025, Quest Diagnostics reported a robust financial performance with revenues reaching $2.65 billion, marking a 12.1% increase from the previous year. The company’s reported diluted earnings per share (EPS) rose by 12.8% to $1.94, while the adjusted diluted EPS increased by 8.3% to $2.21. The company also reaffirmed its revenue and adjusted EPS guidance for the full year 2025.
Key financial metrics highlighted in the report include a 12.7% increase in Diagnostic Information Services revenues and a 12.4% rise in requisition volume. Operating income improved by 15.4%, and cash provided by operations more than doubled compared to the previous year. The company’s strategic focus on acquisitions, enterprise accounts, and advanced diagnostics contributed significantly to its growth.
Looking ahead, Quest Diagnostics maintains a positive outlook for 2025, with expected full-year revenues between $10.70 billion and $10.85 billion. The company anticipates reported diluted EPS to range from $8.62 to $8.87, while adjusted diluted EPS is projected to be between $9.55 and $9.80. This reaffirmation of guidance reflects management’s confidence in the company’s strategic direction and market position.